PECAM1 and neoplasm: During the revascularization phase, tumours obtained following treatment with regorafenib and PDGFRβ antibodies were less revascularized and their CD31 density was remarkably lower than that of tumours obtained following treatment with regorafenib and IgG (Figure 1e and f).